<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220129053861N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-02-11</date_registration>
      <primary_sponsor>Qazvin University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Diclofenac  suppository and Lidocaine  ointment in controling episiotomy site pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of diclofenac suppository with topical lidocaine procaine ointment in controlling episiotomy site pain in primiparous women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61588</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using random allocation softeware software, 120 patients are divided into A and B by balanced block randomization method. The size of each block is 8 and the total number of blocks is 15. There are 60 patients in each group. Therefore, the balanced randomization method for participants is used to study a randomized clinical trial to evaluate the effect of diclofenac suppository and lidocaine-procaine ointment in controlling episiotomy pain.</study_design>
      <phase>3</phase>
      <hc_freetext>Episiotomy pain control.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  Immediately after episiotomy Diclofenac suppository 50mg (Aboreyhan company)is used, then it is repeated every eight hours according to the patient's need with a maximum dose of 150 mg. If the patient does not need it and there is no pain, she can not receive the next dose and if additional painkillers are needed before the specified time,she can use Acetaminophen 500mg(shefa company). Intervention 2: Intervention group: Intervention group: For group B, immediately after delivery, 2.5 ٪ 2.5% topical Lidocaine Procaine cream (Tehranchemie company)is used and then repeated every eight hours according to the patient's needs. The drug is given to the patient 8,16,24 hours later. If the patient does not need it and there is no pain, she can not receive the next dose of the drug. If she needs analgesia before the specified time, she can use acetaminophen 500 mg(shefa company).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
.

When:
.

To whom:
.

Conditions:
.

Where to obtain:
.

How to obtain:
.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Mirzapour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Floor 3,No 11,Fajr 4th alley,Bahar e sharghi street,Sar e Jangal blvd,Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14 7695 3854</zip>
        <telephone>+98 21 4444 0496</telephone>
        <email>Sadafmirzapourr@gmail.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Masoumeh Dadashaliha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleghani street,Kowsar hospital</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۳۴۱۵۶-۱۳۱۷۶</zip>
        <telephone>+98 28 3323 6374</telephone>
        <email>m.dadashaliha@qums.ac.ir</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Primiparous women
Age range 18-40
Spontaneous  onset of labor
Singleton pregnancy
Cephalic presentation of fetus
Mediolateral episiotomy in natural delivery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Postpartum hemorrhage
Use of forceps and vacuum for childbirth
Manual removal of placenta (placenta corage)
Contraindications to Nonsteroidal Anti-inflammatory drugs
Multiple perineal rupture</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  Immediately after episiotomy Diclofenac suppository 50mg (Aboreyhan company)is used, then it is repeated every eight hours according to the patient's need with a maximum dose of 150 mg. If the patient does not need it and there is no pain, she can not receive the next dose and if additional painkillers are needed before the specified time,she can use Acetaminophen 500mg(shefa company)</i_keyword>
      <i_keyword>Intervention group: Intervention group: For group B, immediately after delivery, 2.5 ٪ 2.5% topical Lidocaine Procaine cream (Tehranchemie company)is used and then repeated every eight hours according to the patient's needs. The drug is given to the patient 8,16,24 hours later. If the patient does not need it and there is no pain, she can not receive the next dose of the drug. If she needs analgesia before the specified time, she can use acetaminophen 500 mg(shefa company)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sevirity of Episiotomy site pain. Timepoint: 8,16,24 hour after episiotomy and then day 3 and 7 after episiotomy. Method of measurement: Visual analogue scale.</prim_outcome>
      <prim_outcome>Number of Diclofenac  suppository use. Timepoint: 8,16,24 hour after episiotomy then day 3,7. Method of measurement: Record the frequency of use of medications received.</prim_outcome>
      <prim_outcome>Number of Lidocaine Procaine Ointments use. Timepoint: 8,16,24 hour after episiotomy then day 3,7. Method of measurement: Record the frequency of use of lidocaine procaine ointment.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Frequency of use of additional analgesic. Timepoint: Before the specified time to receive the next dose of analgesia if patient needs. Method of measurement: Record frequency of additional analgesic use.</sec_outcome>
      <sec_outcome>Patient satisfaction. Timepoint: Day 3,7 after episiotomy. Method of measurement: Ask patient by phone.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Qazvin University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-09-19</approval_date>
        <contact_name>Ethics committee of Qazvin University of Medical Science</contact_name>
        <contact_address>Medicine faculty,Qazvin University of Medical Science,Bahonar blvd,Qazvin Qazvin Qazvin Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
